CSE$GMAB
Genmab A/S · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Headline financials
Revenue & EPS history
Genmab · Revenue · Quarterly
kr700M
Q4 2022+73.7%vs Q4 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+293.0%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+6983.2%
Q4 2024
Best reaction
-8.2%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.6% | -2.7% | -10.1% | |
| Q3 2025 | +0.9% | +3.8% | +8.7% | |
| Q1 2025 | -3.4% | -6.3% | +7.8% | |
| Q4 2024 | +6983.2% | +3.6% | +2.8% | |
| Q2 2024 | -0.1% | -5.7% | -12.8% | |
| Q4 2023 | +6.8% | -1.7% | -3.2% | |
| Q3 2023 | +7.5% | +9.0% | +12.2% | |
| Q2 2023 | -5.5% | -5.2% | -3.0% | |
| Q1 2023 | +6.0% | +6.5% | -2.7% | |
| Q4 2022 | -4.8% | -3.5% | -4.8% | |
| Q3 2022 | +8.7% | +6.3% | +13.7% | |
| Q2 2022 | +7.3% | +6.0% | +6.6% | |
| Q1 2022 | -3.8% | -0.2% | -1.9% | |
| Q4 2021 | -3.6% | +0.1% | -16.5% | |
| Q3 2021 | -4.2% | -8.7% | -15.6% | |
| Q2 2021 | +2.6% | +2.1% | -3.1% | |
| Q1 2021 | +4.6% | +4.6% | +15.1% | |
| Q4 2020 | -8.2% | +0.2% | +9.3% | |
| Q3 2020 | +14.7% | +9.2% | +11.8% | |
| Q2 2020 | +5.9% | -5.8% | -4.7% | |
| Q1 2020 | +7.1% | +13.0% | +16.3% | |
| Q4 2019 | +3.9% | +2.5% | -20.1% | |
| Q3 2019 | +1.8% | +2.4% | +10.0% | |
| Q2 2019 | -0.1% | +2.2% | +0.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro